<DOC>
	<DOCNO>NCT02236936</DOCNO>
	<brief_summary>Prevention critical weight loss . In patient Squamous Cell Carcinoma Head Neck ( SCCHN ) weight loss relevant clinical problem radiotherapy might result high treatment relate toxicity discontinuation potential curative treatment . Thus investigator want evaluate efficacy overnight parenteral nutritional ( PN ) support patient SCCHN treat curative radiotherapy ( RTX ) combination Cetuximab ( E ) Cisplatin ( P ) .</brief_summary>
	<brief_title>Parenteral Nutrition Patients Treated Locally Advanced Inoperable Tumors Head Neck</brief_title>
	<detailed_description>The investigator hypothesize 60 % patient receive RTX without supplemental PN suffer critical weight loss 5 % treatment - supplemental overnight PN might result significant improvement nutritional status .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Any patient eligible definitive curative radiochemotherapy Cisplatin radioimmunotherapy Cetuximab . Written inform consent obtain prior study specific screen activity patient able comply protocol . Histologically confirm local advance squamous cell carcinoma Larynx , Hypopharynx , Oropharynx Cavum oris treat definitive radiotherapy combination Cisplatin Cetuximab . p16 status available Age â‰¥ 18 Women childbearing potential must negative pregnancy test screening must use effective contraception . Distant metastasis Prior radiation ( Head neck area ) Pregnant lactate woman History malignancy ; yet patient diseasefree 5 year patient history completely resect nonmelanoma skin cancer successfully treat situ carcinoma eligible . Concurrent cancer therapy ( chemotherapy , immunotherapy , antihormonal biologic therapy ) concurrent treatment investigational drug . Serious medical psychiatric disorder would interfere patient 's safety inform consent . Participation another interventional clinical study time study inclusion ( except followup period without treatment 30 day ) denial simultaneous participation noninterventional study PI study center .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Squamous Cell Carcinoma</keyword>
	<keyword>Head neck</keyword>
	<keyword>SCCHN</keyword>
	<keyword>Parenteral nutrition</keyword>
	<keyword>Larynx</keyword>
	<keyword>Hypopharynx</keyword>
	<keyword>Cavum oris</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>Cisplatin</keyword>
</DOC>